Table 1.
Investigations, radiological changes, and treatment of the patients SOB = shortness of breath; CTV = cycle threshold value; DVT = deep vein thrombosis; CRP = C-reactive protein; LDH = lactate dehydrogenase; PCT = procalcitonin; PT = prothrombin time, PE = pulmonary embolism, *>2 ng/ml indicate high risk of infection.
| Variable | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Normal range |
|---|---|---|---|---|---|
| Age(years)/Sex | 51M | 55M | 60M | 48F | |
| First episode symptoms(D0) | Asymptomatic | Runny nose | Asymptomatic | SOB, fatigue | |
| Day of second episode | D58 | D31 | D 27 | D85 | |
| Second episode symptoms | Fever-cough–SOB- | Fever-Dry cough- sore throat | Cough- SOB | SOB-Fever-vomiting | |
| Co-morbidity | None | Relapsed NHL | IHD, HTN, DM | Metastatic breast cancer | |
| O2 saturation (RA) on second admission | 88% | 93% | 83% | 89% | |
| CXR on a second admission | Bilateral patchy airspace disease | Bilateral patchy airspace disease | Bilateral patchy airspace disease | Bilateral airspace disease | |
| CT-Scan on second admission | Bilateral patchy central and peripheral ground glass opacities (GGO). No PE | Bilateral patchy GGO with thickened interlobular septa and peripheral consolidation. No PE | Not done | Bilateral patchy GGO. No PE | |
| Laboratory investigations during second admission | |||||
| WBC 10^9/l | 5.0 | 4.2 | 3.9 | 3.4 | 4.0 - 11.0 |
| Lymphocytes 10^9/l | 1.1 | 0.4 | 1.5 | .24 | 1.5 - 4.0 |
| Troponin ng/ml | 0.009 | Not done | 0.019 | .304 | 0.1 |
| D-Dimer ug/ml | 0.72 | .58 | 0.760 | 16.11 | .000 - .500 |
| LDH U/l | 349 | 304 | 263 | 514 | 135 - 225 |
| CRP mg/l | 164 | 115 | 19 | 60 | 0 - 6 |
| Ferritin ng/ml | 746 | 3453 | 444 | 4885 | 30 - 400 |
| Fibrinogen g/l | 6.6 | 4.7 | 6.7 | 3.7 | 2.0 - 5.0 |
| PCT ng/ml | 0.39 | 0.17 | 0.08 | 0.70 | * |
| PT sec | 14.0 | 13.1 | 12.5 | 21.9 | 11.5 - 14.5 |
| creatinine umol/l | 120 | 132 | 67 | 67 | 59- 104 |
| Interleukin 6 pg/ml | 9.8 | 43.7 | 11 | Not done | up to 0.7 |
| SARS-COV-2 IgG (Abbot) | 7.04 index positive | 0.01 index negative | Not done | Not done | |
| SARS-CoV-2 PCR (date &CTV) | D0 CTV 27.1, D58 CTV22.2, D62 CTV 21.06 | D0+v, D10-ve, D32 CT 6.41 D42 CTV 10.7 | D0+VE, D27+ve CTV-Not available | D0+ve, D7-ve, D9-ve, D85+ve CTV not available | |
| Treatment | |||||
| Favipravir* | Yes | Yes | Yes | yes | |
| Antibiotic therapy | Yes | Yes | Yes | yes | |
| Dexamethasone | No | yes | yes | ||
| Tocilizumab (400 mg per dose) | Yes (two doses) | No | No | Yes(two doses) | |
| DVT prophylaxis | Yes | Yes | Yes | yes | |